Four service tiers across the full AI deployment lifecycle
From community-level risk intelligence before you procure, through independent assessment of deployed tools, to continuous post-deployment monitoring. Each service is independent, evidence-based, and delivers findings your organisation can act on.
The Four Service Tiers
From proactive risk assessment to continuous post-deployment monitoring. Every engagement is independent, evidence-based, and delivers findings your organisation can act on.
1
Community AI Deployment Profile
◎ Proactive equity risk assessment for your community — before any AI tool is selected
Using publicly available data demystifies community-level equity risk. We process Census data, CDC PLACES, and healthcare disparity tools to produce a catchment area profile. This establishes the community demographic and health profile against which any AI tool's performance can be assessed, requiring no patient records. Results include source selection calibrated to clinical use cases and funding contexts (CMS/NHS). Timeline: 2-3 weeks.
Deliverable: Community AI Deployment Profile.
2
AI Equity Validation Review
â—ŽÂ Rapid independent assessment of a specific AI tool under consideration for procurement
During AI vendor evaluation, we conduct a rapid structured review of vendor documentation, training data claims, validation methodology, and deployment context fit. We produce an AI Equity Risk Profile that places the assessed tool in one of four phases — from Validated for Deployment through to Significant Equity Risk Identified — with recommendations for the specific conditions, contractual requirements, and monitoring protocols appropriate to each phase. This is your independent evidence base. The deployment decision remains yours.
Deliverables: AI Equity Validation Report + AI Equity Risk Profile.
3
Comprehensive AI Equity Assurance Review
â—Ž Comprehensive independent assessment across all seven domains with full regulatory mapping
For AI systems already deployed, the central question is whether they are performing as the vendor claimed — and whether clinical workflows are creating conditions that advantage or disadvantage specific patient populations. The Comprehensive AI Equity Assurance Review answers both. Includes regulatory mapping for the EU AI Act, CMS, and NHS frameworks. We assess deployment readiness with independent clinical and technical rigor. Timeline: 6–10 weeks.
Comprehensive AI Equity Assurance report + Equity Scorecard + Compliance Documentation.
4
AI Equity Performance Monitoring
◎ Continuous post-deployment equity surveillance — your recurring assurance
AI performance drifts over time. Our retainer provides monthly equity reviews, demographic drift detection, and regulatory briefings. Essential for health organizations demonstrating continuous due diligence to boards and regulators. Includes annual full re-assessments at reduced rates.
Monthly Equity Performance Reports + Drift Alerts + Regulatory Updates.
Not a platform. Not a checklist. An independent expert.
We bridge the gap between technical complexity and clinical decision-making. EquiAudit provides the independent rigour hospitals and payers require to evaluate healthcare AI with confidence.
Independent Expertise
Healthcare Specialization
EquiAudit tells health system leaders what the evidence shows about equitable performance — and produces the documented findings required for procurement panels and boards.
Structural Independence
General AI governance platforms lack clinical depth. We audit only healthcare AI, bringing domain knowledge, health equity expertise, and regulatory fluency to every engagement.
Big consulting firms advise the same vendors they audit. EquiAudit has no vendor relationships. Our findings are credible because we have no interest in the procurement outcome.
Not sure which service is right for you?
Book a free 20-minute discovery call. We will listen to where you are in your AI adoption journey and tell you honestly which service — if any — makes sense for your situation.